399 related articles for article (PubMed ID: 24529377)
1. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors.
Croci DO; Cerliani JP; Dalotto-Moreno T; Méndez-Huergo SP; Mascanfroni ID; Dergan-Dylon S; Toscano MA; Caramelo JJ; García-Vallejo JJ; Ouyang J; Mesri EA; Junttila MR; Bais C; Shipp MA; Salatino M; Rabinovich GA
Cell; 2014 Feb; 156(4):744-58. PubMed ID: 24529377
[TBL] [Abstract][Full Text] [Related]
2. Regulatory role of glycans in the control of hypoxia-driven angiogenesis and sensitivity to anti-angiogenic treatment.
Croci DO; Cerliani JP; Pinto NA; Morosi LG; Rabinovich GA
Glycobiology; 2014 Dec; 24(12):1283-90. PubMed ID: 25117007
[TBL] [Abstract][Full Text] [Related]
3. Circulating galectin-1 delineates response to bevacizumab in melanoma patients and reprograms endothelial cell biology.
Bannoud N; Stupirski JC; Cagnoni AJ; Hockl PF; Pérez Sáez JM; García PA; Mahmoud YD; Gambarte Tudela J; Scheidegger MA; Marshall A; Corrie PG; Middleton MR; Mariño KV; Girotti MR; Croci DO; Rabinovich GA
Proc Natl Acad Sci U S A; 2023 Jan; 120(3):e2214350120. PubMed ID: 36634146
[TBL] [Abstract][Full Text] [Related]
4. Glycosylation as new pharmacological strategies for diseases associated with excessive angiogenesis.
Bousseau S; Vergori L; Soleti R; Lenaers G; Martinez MC; Andriantsitohaina R
Pharmacol Ther; 2018 Nov; 191():92-122. PubMed ID: 29909237
[TBL] [Abstract][Full Text] [Related]
5. Galectin-1 Pulls the Strings on VEGFR2.
Stanley P
Cell; 2014 Feb; 156(4):625-6. PubMed ID: 24529367
[TBL] [Abstract][Full Text] [Related]
6. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Leite de Oliveira R; Hamm A; Mazzone M
Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
[TBL] [Abstract][Full Text] [Related]
7. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
Jain RK
Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
[TBL] [Abstract][Full Text] [Related]
8. Glycosylation controls cooperative PECAM-VEGFR2-β3 integrin functions at the endothelial surface for tumor angiogenesis.
Imamaki R; Ogawa K; Kizuka Y; Komi Y; Kojima S; Kotani N; Honke K; Honda T; Taniguchi N; Kitazume S
Oncogene; 2018 Aug; 37(31):4287-4299. PubMed ID: 29717262
[TBL] [Abstract][Full Text] [Related]
9. The direct effects of anti-vascular endothelial growth factor therapy on tumor cells.
Moser C; Lang SA; Stoeltzing O
Clin Colorectal Cancer; 2007 Jul; 6(8):564-71. PubMed ID: 17681102
[TBL] [Abstract][Full Text] [Related]
10. [VEGF and its receptors as therapeutic target in cancer therapy].
Gisterek I; Kornafel J
Przegl Lek; 2006; 63(3):155-7. PubMed ID: 16967703
[TBL] [Abstract][Full Text] [Related]
11. The multifaceted activity of VEGF in angiogenesis - Implications for therapy responses.
Moens S; Goveia J; Stapor PC; Cantelmo AR; Carmeliet P
Cytokine Growth Factor Rev; 2014 Aug; 25(4):473-82. PubMed ID: 25169850
[TBL] [Abstract][Full Text] [Related]
12. VEGF inhibitors in brain tumors.
Brastianos PK; Batchelor TT
Clin Adv Hematol Oncol; 2009 Nov; 7(11):753-60, 768. PubMed ID: 20075834
[TBL] [Abstract][Full Text] [Related]
13. Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature.
Frischer JS; Huang J; Serur A; Kadenhe-Chiweshe A; McCrudden KW; O'Toole K; Holash J; Yancopoulos GD; Yamashiro DJ; Kandel JJ
Int J Oncol; 2004 Sep; 25(3):549-53. PubMed ID: 15289855
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.
Tugues S; Koch S; Gualandi L; Li X; Claesson-Welsh L
Mol Aspects Med; 2011 Apr; 32(2):88-111. PubMed ID: 21565214
[TBL] [Abstract][Full Text] [Related]
15. Galectin-1 Controls the Proliferation and Migration of Liver Sinusoidal Endothelial Cells and Their Interaction With Hepatocarcinoma Cells.
Manzi M; Bacigalupo ML; Carabias P; Elola MT; Wolfenstein-Todel C; Rabinovich GA; Espelt MV; Troncoso MF
J Cell Physiol; 2016 Jul; 231(7):1522-33. PubMed ID: 26551914
[TBL] [Abstract][Full Text] [Related]
16. Anti-vascular endothelial growth factor therapy in the era of personalized medicine.
Féliz LR; Tsimberidou AM
Cancer Chemother Pharmacol; 2013 Jul; 72(1):1-12. PubMed ID: 23463481
[TBL] [Abstract][Full Text] [Related]
17. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
18. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
Hicklin DJ; Ellis LM
J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754
[TBL] [Abstract][Full Text] [Related]
19. The vascular endothelial growth factors and receptors family: Up to now the only target for anti-angiogenesis therapy.
Tarallo V; De Falco S
Int J Biochem Cell Biol; 2015 Jul; 64():185-9. PubMed ID: 25936669
[TBL] [Abstract][Full Text] [Related]
20. Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature.
Korpanty G; Carbon JG; Grayburn PA; Fleming JB; Brekken RA
Clin Cancer Res; 2007 Jan; 13(1):323-30. PubMed ID: 17200371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
